APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Oral Medications for Multiple Sclerosis

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Oral Medications for Multiple Sclerosis Market Analysis and Forecast 2026-2032

Report ID 174019970227 December 2025216 pages

Choose your research edition.

Industry ResearchOral Medications for Multiple Sclerosis Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral Medications for Multiple Sclerosis Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Oral Medications for Multiple Sclerosis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral Medications for Multiple Sclerosis Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral Medications for Multiple Sclerosis Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Oral Medications for Multiple Sclerosis market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Oral Medications for Multiple Sclerosis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Oral Medications for Multiple Sclerosis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Oral Medications for Multiple Sclerosis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Oral Medications for Multiple Sclerosis is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Oral Medications for Multiple Sclerosis include Sichuan Omnis Pharmaceutical, CGeneTech (Suzhou, China), Qilu Pharmaceutical, Nanjing Healthnice Pharmaceutical, HEC Pharm, Cisen Pharmaceutical, Zydus, Viatris and Teva, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Oral Medications for Multiple Sclerosis, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Oral Medications for Multiple Sclerosis, also provides the sales of main regions and countries. Of the upcoming market potential for Oral Medications for Multiple Sclerosis, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oral Medications for Multiple Sclerosis sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Oral Medications for Multiple Sclerosis market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Oral Medications for Multiple Sclerosis sales, projected growth trends, production technology, application and end-user industry.

Oral Medications for Multiple Sclerosis Segment by Company

Sichuan Omnis Pharmaceutical

CGeneTech (Suzhou, China)

Qilu Pharmaceutical

Nanjing Healthnice Pharmaceutical

HEC Pharm

Cisen Pharmaceutical

Zydus

Viatris

Teva

Sun Pharmaceuticals

Sanofi

Sandoz

Novartis

Mylan

Merck

Janssen

Glenmark Pharmaceuticals

Dr. Reddy's Laboratories

Bristol Myers Squibb

Biogen

Banner Life Sciences

Apotex

Alembic

Accord Healthcare

Oral Medications for Multiple Sclerosis Segment by Type

Ozanimod

Ponesimod

Fingolimod

Diroximel Fumarate

Monomethyl Fumarate

Dimethyl Fumarate

Cladribine

Teriflunomide

Siponimod

Oral Medications for Multiple Sclerosis Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Oral Medications for Multiple Sclerosis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Medications for Multiple Sclerosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral Medications for Multiple Sclerosis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Medications for Multiple Sclerosis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Oral Medications for Multiple Sclerosis in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Oral Medications for Multiple Sclerosis manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oral Medications for Multiple Sclerosis sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oral Medications for Multiple Sclerosis Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Ozanimod Major Manufacturers Table 3. Ponesimod Major Manufacturers Table 4. Fingolimod Major Manufacturers Table 5. Diroximel Fumarate Major Manufacturers Table 6. Monomethyl Fumarate Major Manufacturers Table 7. Dimethyl Fumarate Major Manufacturers Table 8. Cladribine Major Manufacturers Table 9. Teriflunomide Major Manufacturers Table 10. Siponimod Major Manufacturers Table 11. Global Oral Medications for Multiple Sclerosis Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 12. Hospital and Clinic Major Manufacturers Table 13. Retail Pharmacies Major Manufacturers Table 14. Other Major Manufacturers Table 15. Oral Medications for Multiple Sclerosis Industry Trends Table 16. Oral Medications for Multiple Sclerosis Industry Drivers Table 17. Oral Medications for Multiple Sclerosis Industry Opportunities and Challenges Table 18. Oral Medications for Multiple Sclerosis Industry Restraints Table 19. Global Oral Medications for Multiple Sclerosis Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Oral Medications for Multiple Sclerosis Revenue by Region (2021-2026) & (US$ Million) Table 21. Global Oral Medications for Multiple Sclerosis Revenue by Region (2027-2032) & (US$ Million) Table 22. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Region (2021-2026) Table 23. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Region (2027-2032) Table 24. Global Oral Medications for Multiple Sclerosis Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 25. Global Oral Medications for Multiple Sclerosis Sales by Region (2021-2026) & (K Units) Table 26. Global Oral Medications for Multiple Sclerosis Sales by Region (2027-2032) & (K Units) Table 27. Global Oral Medications for Multiple Sclerosis Sales Market Share by Region (2021-2026) Table 28. Global Oral Medications for Multiple Sclerosis Sales Market Share by Region (2027-2032) Table 29. Global Oral Medications for Multiple Sclerosis Revenue by Manufacturers (US$ Million) & (2021-2026) Table 30. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Manufacturers (2021-2026) Table 31. Global Oral Medications for Multiple Sclerosis Sales by Manufacturers (US$ Million) & (2021-2026) Table 32. Global Oral Medications for Multiple Sclerosis Sales Market Share by Manufacturers (2021-2026) Table 33. Global Oral Medications for Multiple Sclerosis Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 34. Global Oral Medications for Multiple Sclerosis Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 35. Global Oral Medications for Multiple Sclerosis Key Manufacturers Manufacturing Sites & Headquarters Table 36. Global Oral Medications for Multiple Sclerosis Manufacturers, Product Type & Application Table 37. Global Oral Medications for Multiple Sclerosis Manufacturers' Establishment Date Table 38. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 39. Global Oral Medications for Multiple Sclerosis by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Oral Medications for Multiple Sclerosis Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Oral Medications for Multiple Sclerosis Revenue by Type (2021-2026) & (US$ Million) Table 42. Global Oral Medications for Multiple Sclerosis Revenue by Type (2027-2032) & (US$ Million) Table 43. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Type (2021-2026) Table 44. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Type (2027-2032) Table 45. Global Oral Medications for Multiple Sclerosis Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 46. Global Oral Medications for Multiple Sclerosis Sales by Type (2021-2026) & (K Units) Table 47. Global Oral Medications for Multiple Sclerosis Sales by Type (2027-2032) & (K Units) Table 48. Global Oral Medications for Multiple Sclerosis Sales Market Share by Type (2021-2026) Table 49. Global Oral Medications for Multiple Sclerosis Sales Market Share by Type (2027-2032) Table 50. Global Oral Medications for Multiple Sclerosis Price by Type (2021-2026) & (US$/Unit) Table 51. Global Oral Medications for Multiple Sclerosis Price by Type (2027-2032) & (US$/Unit) Table 52. Global Oral Medications for Multiple Sclerosis Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Oral Medications for Multiple Sclerosis Revenue by Application (2021-2026) & (US$ Million) Table 54. Global Oral Medications for Multiple Sclerosis Revenue by Application (2027-2032) & (US$ Million) Table 55. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Application (2021-2026) Table 56. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Application (2027-2032) Table 57. Global Oral Medications for Multiple Sclerosis Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 58. Global Oral Medications for Multiple Sclerosis Sales by Application (2021-2026) & (K Units) Table 59. Global Oral Medications for Multiple Sclerosis Sales by Application (2027-2032) & (K Units) Table 60. Global Oral Medications for Multiple Sclerosis Sales Market Share by Application (2021-2026) Table 61. Global Oral Medications for Multiple Sclerosis Sales Market Share by Application (2027-2032) Table 62. Global Oral Medications for Multiple Sclerosis Price by Application (2021-2026) & (US$/Unit) Table 63. Global Oral Medications for Multiple Sclerosis Price by Application (2027-2032) & (US$/Unit) Table 64. Sichuan Omnis Pharmaceutical Company Information Table 65. Sichuan Omnis Pharmaceutical Business Overview Table 66. Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio Table 68. Sichuan Omnis Pharmaceutical Recent Development Table 69. CGeneTech (Suzhou, China) Company Information Table 70. CGeneTech (Suzhou, China) Business Overview Table 71. CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Product Portfolio Table 73. CGeneTech (Suzhou, China) Recent Development Table 74. Qilu Pharmaceutical Company Information Table 75. Qilu Pharmaceutical Business Overview Table 76. Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio Table 78. Qilu Pharmaceutical Recent Development Table 79. Nanjing Healthnice Pharmaceutical Company Information Table 80. Nanjing Healthnice Pharmaceutical Business Overview Table 81. Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio Table 83. Nanjing Healthnice Pharmaceutical Recent Development Table 84. HEC Pharm Company Information Table 85. HEC Pharm Business Overview Table 86. HEC Pharm Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. HEC Pharm Oral Medications for Multiple Sclerosis Product Portfolio Table 88. HEC Pharm Recent Development Table 89. Cisen Pharmaceutical Company Information Table 90. Cisen Pharmaceutical Business Overview Table 91. Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio Table 93. Cisen Pharmaceutical Recent Development Table 94. Zydus Company Information Table 95. Zydus Business Overview Table 96. Zydus Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Zydus Oral Medications for Multiple Sclerosis Product Portfolio Table 98. Zydus Recent Development Table 99. Viatris Company Information Table 100. Viatris Business Overview Table 101. Viatris Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Viatris Oral Medications for Multiple Sclerosis Product Portfolio Table 103. Viatris Recent Development Table 104. Teva Company Information Table 105. Teva Business Overview Table 106. Teva Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Teva Oral Medications for Multiple Sclerosis Product Portfolio Table 108. Teva Recent Development Table 109. Sun Pharmaceuticals Company Information Table 110. Sun Pharmaceuticals Business Overview Table 111. Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio Table 113. Sun Pharmaceuticals Recent Development Table 114. Sanofi Company Information Table 115. Sanofi Business Overview Table 116. Sanofi Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Sanofi Oral Medications for Multiple Sclerosis Product Portfolio Table 118. Sanofi Recent Development Table 119. Sandoz Company Information Table 120. Sandoz Business Overview Table 121. Sandoz Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Sandoz Oral Medications for Multiple Sclerosis Product Portfolio Table 123. Sandoz Recent Development Table 124. Novartis Company Information Table 125. Novartis Business Overview Table 126. Novartis Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Novartis Oral Medications for Multiple Sclerosis Product Portfolio Table 128. Novartis Recent Development Table 129. Mylan Company Information Table 130. Mylan Business Overview Table 131. Mylan Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Mylan Oral Medications for Multiple Sclerosis Product Portfolio Table 133. Mylan Recent Development Table 134. Merck Company Information Table 135. Merck Business Overview Table 136. Merck Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Merck Oral Medications for Multiple Sclerosis Product Portfolio Table 138. Merck Recent Development Table 139. Janssen Company Information Table 140. Janssen Business Overview Table 141. Janssen Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Janssen Oral Medications for Multiple Sclerosis Product Portfolio Table 143. Janssen Recent Development Table 144. Glenmark Pharmaceuticals Company Information Table 145. Glenmark Pharmaceuticals Business Overview Table 146. Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio Table 148. Glenmark Pharmaceuticals Recent Development Table 149. Dr. Reddy's Laboratories Company Information Table 150. Dr. Reddy's Laboratories Business Overview Table 151. Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Product Portfolio Table 153. Dr. Reddy's Laboratories Recent Development Table 154. Bristol Myers Squibb Company Information Table 155. Bristol Myers Squibb Business Overview Table 156. Bristol Myers Squibb Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Bristol Myers Squibb Oral Medications for Multiple Sclerosis Product Portfolio Table 158. Bristol Myers Squibb Recent Development Table 159. Biogen Company Information Table 160. Biogen Business Overview Table 161. Biogen Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. Biogen Oral Medications for Multiple Sclerosis Product Portfolio Table 163. Biogen Recent Development Table 164. Banner Life Sciences Company Information Table 165. Banner Life Sciences Business Overview Table 166. Banner Life Sciences Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 167. Banner Life Sciences Oral Medications for Multiple Sclerosis Product Portfolio Table 168. Banner Life Sciences Recent Development Table 169. Apotex Company Information Table 170. Apotex Business Overview Table 171. Apotex Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 172. Apotex Oral Medications for Multiple Sclerosis Product Portfolio Table 173. Apotex Recent Development Table 174. Alembic Company Information Table 175. Alembic Business Overview Table 176. Alembic Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 177. Alembic Oral Medications for Multiple Sclerosis Product Portfolio Table 178. Alembic Recent Development Table 179. Accord Healthcare Company Information Table 180. Accord Healthcare Business Overview Table 181. Accord Healthcare Oral Medications for Multiple Sclerosis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 182. Accord Healthcare Oral Medications for Multiple Sclerosis Product Portfolio Table 183. Accord Healthcare Recent Development Table 184. North America Oral Medications for Multiple Sclerosis Revenue by Type (2021-2026) & (US$ Million) Table 185. North America Oral Medications for Multiple Sclerosis Revenue by Type (2027-2032) & (US$ Million) Table 186. North America Oral Medications for Multiple Sclerosis Sales by Type (2021-2026) & (K Units) Table 187. North America Oral Medications for Multiple Sclerosis Sales by Type (2027-2032) & (K Units) Table 188. North America Oral Medications for Multiple Sclerosis Sales Price by Type (2021-2026) & (US$/Unit) Table 189. North America Oral Medications for Multiple Sclerosis Sales Price by Type (2027-2032) & (US$/Unit) Table 190. North America Oral Medications for Multiple Sclerosis Revenue by Application (2021-2026) & (US$ Million) Table 191. North America Oral Medications for Multiple Sclerosis Revenue by Application (2027-2032) & (US$ Million) Table 192. North America Oral Medications for Multiple Sclerosis Sales by Application (2021-2026) & (K Units) Table 193. North America Oral Medications for Multiple Sclerosis Sales by Application (2027-2032) & (K Units) Table 194. North America Oral Medications for Multiple Sclerosis Sales Price by Application (2021-2026) & (US$/Unit) Table 195. North America Oral Medications for Multiple Sclerosis Sales Price by Application (2027-2032) & (US$/Unit) Table 196. North America Oral Medications for Multiple Sclerosis Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 197. North America Oral Medications for Multiple Sclerosis Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 198. North America Oral Medications for Multiple Sclerosis Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 199. North America Oral Medications for Multiple Sclerosis Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 200. North America Oral Medications for Multiple Sclerosis Sales by Country (2021-2026) & (K Units) Table 201. North America Oral Medications for Multiple Sclerosis Sales by Country (2027-2032) & (K Units) Table 202. North America Oral Medications for Multiple Sclerosis Sales Price by Country (2021-2026) & (US$/Unit) Table 203. North America Oral Medications for Multiple Sclerosis Sales Price by Country (2027-2032) & (US$/Unit) Table 204. United States Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 205. Canada Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 206. Mexico Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 207. Europe Oral Medications for Multiple Sclerosis Revenue by Type (2021-2026) & (US$ Million) Table 208. Europe Oral Medications for Multiple Sclerosis Revenue by Type (2027-2032) & (US$ Million) Table 209. Europe Oral Medications for Multiple Sclerosis Sales by Type (2021-2026) & (K Units) Table 210. Europe Oral Medications for Multiple Sclerosis Sales by Type (2027-2032) & (K Units) Table 211. Europe Oral Medications for Multiple Sclerosis Sales Price by Type (2021-2026) & (US$/Unit) Table 212. Europe Oral Medications for Multiple Sclerosis Sales Price by Type (2027-2032) & (US$/Unit) Table 213. Europe Oral Medications for Multiple Sclerosis Revenue by Application (2021-2026) & (US$ Million) Table 214. Europe Oral Medications for Multiple Sclerosis Revenue by Application (2027-2032) & (US$ Million) Table 215. Europe Oral Medications for Multiple Sclerosis Sales by Application (2021-2026) & (K Units) Table 216. Europe Oral Medications for Multiple Sclerosis Sales by Application (2027-2032) & (K Units) Table 217. Europe Oral Medications for Multiple Sclerosis Sales Price by Application (2021-2026) & (US$/Unit) Table 218. Europe Oral Medications for Multiple Sclerosis Sales Price by Application (2027-2032) & (US$/Unit) Table 219. Europe Oral Medications for Multiple Sclerosis Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 220. Europe Oral Medications for Multiple Sclerosis Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 221. Europe Oral Medications for Multiple Sclerosis Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 222. Europe Oral Medications for Multiple Sclerosis Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 223. Europe Oral Medications for Multiple Sclerosis Sales by Country (2021-2026) & (K Units) Table 224. Europe Oral Medications for Multiple Sclerosis Sales by Country (2027-2032) & (K Units) Table 225. Europe Oral Medications for Multiple Sclerosis Sales Price by Country (2021-2026) & (US$/Unit) Table 226. Europe Oral Medications for Multiple Sclerosis Sales Price by Country (2027-2032) & (US$/Unit) Table 227. Germany Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 228. France Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 229. U.K. Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 230. Italy Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 231. Russia Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 232. Spain Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 233. Netherlands Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 234. Switzerland Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 235. Sweden Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 236. Poland Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 237. China Oral Medications for Multiple Sclerosis Revenue by Type (2021-2026) & (US$ Million) Table 238. China Oral Medications for Multiple Sclerosis Revenue by Type (2027-2032) & (US$ Million) Table 239. China Oral Medications for Multiple Sclerosis Sales by Type (2021-2026) & (K Units) Table 240. China Oral Medications for Multiple Sclerosis Sales by Type (2027-2032) & (K Units) Table 241. China Oral Medications for Multiple Sclerosis Sales Price by Type (2021-2026) & (US$/Unit) Table 242. China Oral Medications for Multiple Sclerosis Sales Price by Type (2027-2032) & (US$/Unit) Table 243. China Oral Medications for Multiple Sclerosis Revenue by Application (2021-2026) & (US$ Million) Table 244. China Oral Medications for Multiple Sclerosis Revenue by Application (2027-2032) & (US$ Million) Table 245. China Oral Medications for Multiple Sclerosis Sales by Application (2021-2026) & (K Units) Table 246. China Oral Medications for Multiple Sclerosis Sales by Application (2027-2032) & (K Units) Table 247. China Oral Medications for Multiple Sclerosis Sales Price by Application (2021-2026) & (US$/Unit) Table 248. China Oral Medications for Multiple Sclerosis Sales Price by Application (2027-2032) & (US$/Unit) Table 249. Asia Oral Medications for Multiple Sclerosis Revenue by Type (2021-2026) & (US$ Million) Table 250. Asia Oral Medications for Multiple Sclerosis Revenue by Type (2027-2032) & (US$ Million) Table 251. Asia Oral Medications for Multiple Sclerosis Sales by Type (2021-2026) & (K Units) Table 252. Asia Oral Medications for Multiple Sclerosis Sales by Type (2027-2032) & (K Units) Table 253. Asia Oral Medications for Multiple Sclerosis Sales Price by Type (2021-2026) & (US$/Unit) Table 254. Asia Oral Medications for Multiple Sclerosis Sales Price by Type (2027-2032) & (US$/Unit) Table 255. Asia Oral Medications for Multiple Sclerosis Revenue by Application (2021-2026) & (US$ Million) Table 256. Asia Oral Medications for Multiple Sclerosis Revenue by Application (2027-2032) & (US$ Million) Table 257. Asia Oral Medications for Multiple Sclerosis Sales by Application (2021-2026) & (K Units) Table 258. Asia Oral Medications for Multiple Sclerosis Sales by Application (2027-2032) & (K Units) Table 259. Asia Oral Medications for Multiple Sclerosis Sales Price by Application (2021-2026) & (US$/Unit) Table 260. Asia Oral Medications for Multiple Sclerosis Sales Price by Application (2027-2032) & (US$/Unit) Table 261. Asia Oral Medications for Multiple Sclerosis Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 262. Asia Oral Medications for Multiple Sclerosis Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 263. Asia Oral Medications for Multiple Sclerosis Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 264. Asia Oral Medications for Multiple Sclerosis Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 265. Asia Oral Medications for Multiple Sclerosis Sales by Country (2021-2026) & (K Units) Table 266. Asia Oral Medications for Multiple Sclerosis Sales by Country (2027-2032) & (K Units) Table 267. Asia Oral Medications for Multiple Sclerosis Sales Price by Country (2021-2026) & (US$/Unit) Table 268. Asia Oral Medications for Multiple Sclerosis Sales Price by Country (2027-2032) & (US$/Unit) Table 269. Japan Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 270. South Korea Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 271. India Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 272. Australia Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 273. Taiwan Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 274. Southeast Asia Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 275. SAMEA Oral Medications for Multiple Sclerosis Revenue by Type (2021-2026) & (US$ Million) Table 276. SAMEA Oral Medications for Multiple Sclerosis Revenue by Type (2027-2032) & (US$ Million) Table 277. SAMEA Oral Medications for Multiple Sclerosis Sales by Type (2021-2026) & (K Units) Table 278. SAMEA Oral Medications for Multiple Sclerosis Sales by Type (2027-2032) & (K Units) Table 279. SAMEA Oral Medications for Multiple Sclerosis Sales Price by Type (2021-2026) & (US$/Unit) Table 280. SAMEA Oral Medications for Multiple Sclerosis Sales Price by Type (2027-2032) & (US$/Unit) Table 281. SAMEA Oral Medications for Multiple Sclerosis Revenue by Application (2021-2026) & (US$ Million) Table 282. SAMEA Oral Medications for Multiple Sclerosis Revenue by Application (2027-2032) & (US$ Million) Table 283. SAMEA Oral Medications for Multiple Sclerosis Sales by Application (2021-2026) & (K Units) Table 284. SAMEA Oral Medications for Multiple Sclerosis Sales by Application (2027-2032) & (K Units) Table 285. SAMEA Oral Medications for Multiple Sclerosis Sales Price by Application (2021-2026) & (US$/Unit) Table 286. SAMEA Oral Medications for Multiple Sclerosis Sales Price by Application (2027-2032) & (US$/Unit) Table 287. SAMEA Oral Medications for Multiple Sclerosis Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 288. SAMEA Oral Medications for Multiple Sclerosis Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 289. SAMEA Oral Medications for Multiple Sclerosis Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 290. SAMEA Oral Medications for Multiple Sclerosis Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 291. SAMEA Oral Medications for Multiple Sclerosis Sales by Country (2021-2026) & (K Units) Table 292. SAMEA Oral Medications for Multiple Sclerosis Sales by Country (2027-2032) & (K Units) Table 293. SAMEA Oral Medications for Multiple Sclerosis Sales Price by Country (2021-2026) & (US$/Unit) Table 294. SAMEA Oral Medications for Multiple Sclerosis Sales Price by Country (2027-2032) & (US$/Unit) Table 295. Brazil Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 296. Argentina Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 297. Chile Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 298. Colombia Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 299. Peru Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 300. Saudi Arabia Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 301. Israel Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 302. UAE Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 303. Turkey Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 304. Iran Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 305. Egypt Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Table 306. Key Raw Materials Table 307. Raw Materials Key Suppliers Table 308. Oral Medications for Multiple Sclerosis Distributors List Table 309. Oral Medications for Multiple Sclerosis Customers List Table 310. Research Programs/Design for This Report Table 311. Authors List of This Report Table 312. Secondary Sources Table 313. Primary Sources List of Figures Figure 1. Oral Medications for Multiple Sclerosis Image Figure 2. Global Oral Medications for Multiple Sclerosis Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral Medications for Multiple Sclerosis Market Size Share 2021 VS 2025 VS 2032 Figure 4. Ozanimod Image Figure 5. Ponesimod Image Figure 6. Fingolimod Image Figure 7. Diroximel Fumarate Image Figure 8. Monomethyl Fumarate Image Figure 9. Dimethyl Fumarate Image Figure 10. Cladribine Image Figure 11. Teriflunomide Image Figure 12. Siponimod Image Figure 13. Global Oral Medications for Multiple Sclerosis Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Oral Medications for Multiple Sclerosis Market Size Share 2021 VS 2025 VS 2032 Figure 15. Hospital and Clinic Image Figure 16. Retail Pharmacies Image Figure 17. Other Image Figure 18. Global Oral Medications for Multiple Sclerosis Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 19. Global Oral Medications for Multiple Sclerosis Revenue (2021-2032) & (US$ Million) Figure 20. Global Oral Medications for Multiple Sclerosis Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Region: 2025 Versus 2032 Figure 22. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Region (2021-2032) Figure 23. Global Oral Medications for Multiple Sclerosis Sales (2021-2032) & (K Units) Figure 24. Global Oral Medications for Multiple Sclerosis Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 25. Global Oral Medications for Multiple Sclerosis Sales Market Share by Region (2021-2032) Figure 26. US & Canada & Mexico Oral Medications for Multiple Sclerosis Sales YoY (2021-2032) & (K Units) Figure 27. Europe Oral Medications for Multiple Sclerosis Sales YoY (2021-2032) & (K Units) Figure 28. China Oral Medications for Multiple Sclerosis Sales YoY (2021-2032) & (K Units) Figure 29. Asia (Excluding China) Oral Medications for Multiple Sclerosis Sales YoY (2021-2032) & (K Units) Figure 30. South America, Middle East and Africa Oral Medications for Multiple Sclerosis Sales YoY (2021-2032) & (K Units) Figure 31. Global Oral Medications for Multiple Sclerosis Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 32. Global Oral Medications for Multiple Sclerosis Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 33. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 34. Global Oral Medications for Multiple Sclerosis Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 36. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Type (2021-2032) Figure 37. Global Oral Medications for Multiple Sclerosis Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 38. Global Oral Medications for Multiple Sclerosis Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 39. Global Oral Medications for Multiple Sclerosis Sales Market Share by Type (2021-2032) Figure 40. Global Oral Medications for Multiple Sclerosis Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 41. Global Oral Medications for Multiple Sclerosis Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 42. Global Oral Medi

Scope & coverage.

Types
  • Ozanimod
  • Ponesimod
  • Fingolimod
  • Diroximel Fumarate
  • Monomethyl Fumarate
  • Dimethyl Fumarate
  • Cladribine
  • Teriflunomide
  • Siponimod
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Sichuan Omnis Pharmaceutical
  • CGeneTech (Suzhou, China)
  • Qilu Pharmaceutical
  • Nanjing Healthnice Pharmaceutical
  • HEC Pharm
  • Cisen Pharmaceutical
  • Zydus
  • Viatris
  • Teva
  • Sun Pharmaceuticals
  • Sanofi
  • Sandoz
  • Novartis
  • Mylan
  • Merck
  • Janssen
  • Glenmark Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Bristol Myers Squibb
  • Biogen
  • Banner Life Sciences
  • Apotex
  • Alembic
  • Accord Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Oral Medications for Multiple Sclerosis Market by Type
  3. 1.2.1 Global Oral Medications for Multiple Sclerosis Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Ozanimod
  5. 1.2.3 Ponesimod
  6. 1.2.4 Fingolimod
  7. 1.2.5 Diroximel Fumarate
  8. 1.2.6 Monomethyl Fumarate
  9. 1.2.7 Dimethyl Fumarate
  10. 1.2.8 Cladribine
  11. 1.2.9 Teriflunomide
  12. 1.2.10 Siponimod
  13. 1.3 Oral Medications for Multiple Sclerosis Market by Application
  14. 1.3.1 Global Oral Medications for Multiple Sclerosis Market Size by Application, 2021 VS 2025 VS 2032
  15. 1.3.2 Hospital and Clinic
  16. 1.3.3 Retail Pharmacies
  17. 1.3.4 Other
  18. 1.4 Assumptions and Limitations
  19. 1.5 Study Goals and Objectives
2 Oral Medications for Multiple Sclerosis Market Dynamics
  1. 2.1 Oral Medications for Multiple Sclerosis Industry Trends
  2. 2.2 Oral Medications for Multiple Sclerosis Industry Drivers
  3. 2.3 Oral Medications for Multiple Sclerosis Industry Opportunities and Challenges
  4. 2.4 Oral Medications for Multiple Sclerosis Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Oral Medications for Multiple Sclerosis Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Oral Medications for Multiple Sclerosis Revenue by Region
  3. 3.2.1 Global Oral Medications for Multiple Sclerosis Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Oral Medications for Multiple Sclerosis Revenue by Region (2021-2026)
  5. 3.2.3 Global Oral Medications for Multiple Sclerosis Revenue by Region (2027-2032)
  6. 3.2.4 Global Oral Medications for Multiple Sclerosis Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Oral Medications for Multiple Sclerosis Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Oral Medications for Multiple Sclerosis Sales by Region
  9. 3.4.1 Global Oral Medications for Multiple Sclerosis Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Oral Medications for Multiple Sclerosis Sales by Region (2021-2026)
  11. 3.4.3 Global Oral Medications for Multiple Sclerosis Sales by Region (2027-2032)
  12. 3.4.4 Global Oral Medications for Multiple Sclerosis Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Oral Medications for Multiple Sclerosis Revenue by Manufacturers
  2. 4.1.1 Global Oral Medications for Multiple Sclerosis Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Oral Medications for Multiple Sclerosis Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Oral Medications for Multiple Sclerosis Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Oral Medications for Multiple Sclerosis Sales by Manufacturers
  6. 4.2.1 Global Oral Medications for Multiple Sclerosis Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Oral Medications for Multiple Sclerosis Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Oral Medications for Multiple Sclerosis Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Oral Medications for Multiple Sclerosis Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Oral Medications for Multiple Sclerosis Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Oral Medications for Multiple Sclerosis Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Oral Medications for Multiple Sclerosis Manufacturers, Product Type & Application
  13. 4.7 Global Oral Medications for Multiple Sclerosis Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Oral Medications for Multiple Sclerosis Market CR5 and HHI
  16. 4.8.2 2025 Oral Medications for Multiple Sclerosis Tier 1, Tier 2, and Tier 3
5 Oral Medications for Multiple Sclerosis Market by Type
  1. 5.1 Global Oral Medications for Multiple Sclerosis Revenue by Type
  2. 5.1.1 Global Oral Medications for Multiple Sclerosis Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Oral Medications for Multiple Sclerosis Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Oral Medications for Multiple Sclerosis Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Oral Medications for Multiple Sclerosis Sales by Type
  6. 5.2.1 Global Oral Medications for Multiple Sclerosis Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Oral Medications for Multiple Sclerosis Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Oral Medications for Multiple Sclerosis Sales Market Share by Type (2021-2032)
  9. 5.3 Global Oral Medications for Multiple Sclerosis Price by Type
6 Oral Medications for Multiple Sclerosis Market by Application
  1. 6.1 Global Oral Medications for Multiple Sclerosis Revenue by Application
  2. 6.1.1 Global Oral Medications for Multiple Sclerosis Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Oral Medications for Multiple Sclerosis Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Oral Medications for Multiple Sclerosis Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Oral Medications for Multiple Sclerosis Sales by Application
  6. 6.2.1 Global Oral Medications for Multiple Sclerosis Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Oral Medications for Multiple Sclerosis Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Oral Medications for Multiple Sclerosis Sales Market Share by Application (2021-2032)
  9. 6.3 Global Oral Medications for Multiple Sclerosis Price by Application
7 Company Profiles
  1. 7.1 Sichuan Omnis Pharmaceutical
  2. 7.1.1 Sichuan Omnis Pharmaceutical Company Information
  3. 7.1.2 Sichuan Omnis Pharmaceutical Business Overview
  4. 7.1.3 Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Sichuan Omnis Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
  6. 7.1.5 Sichuan Omnis Pharmaceutical Recent Developments
  7. 7.2 CGeneTech (Suzhou, China)
  8. 7.2.1 CGeneTech (Suzhou, China) Company Information
  9. 7.2.2 CGeneTech (Suzhou, China) Business Overview
  10. 7.2.3 CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 CGeneTech (Suzhou, China) Oral Medications for Multiple Sclerosis Product Portfolio
  12. 7.2.5 CGeneTech (Suzhou, China) Recent Developments
  13. 7.3 Qilu Pharmaceutical
  14. 7.3.1 Qilu Pharmaceutical Company Information
  15. 7.3.2 Qilu Pharmaceutical Business Overview
  16. 7.3.3 Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Qilu Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
  18. 7.3.5 Qilu Pharmaceutical Recent Developments
  19. 7.4 Nanjing Healthnice Pharmaceutical
  20. 7.4.1 Nanjing Healthnice Pharmaceutical Company Information
  21. 7.4.2 Nanjing Healthnice Pharmaceutical Business Overview
  22. 7.4.3 Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Nanjing Healthnice Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
  24. 7.4.5 Nanjing Healthnice Pharmaceutical Recent Developments
  25. 7.5 HEC Pharm
  26. 7.5.1 HEC Pharm Company Information
  27. 7.5.2 HEC Pharm Business Overview
  28. 7.5.3 HEC Pharm Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 HEC Pharm Oral Medications for Multiple Sclerosis Product Portfolio
  30. 7.5.5 HEC Pharm Recent Developments
  31. 7.6 Cisen Pharmaceutical
  32. 7.6.1 Cisen Pharmaceutical Company Information
  33. 7.6.2 Cisen Pharmaceutical Business Overview
  34. 7.6.3 Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Cisen Pharmaceutical Oral Medications for Multiple Sclerosis Product Portfolio
  36. 7.6.5 Cisen Pharmaceutical Recent Developments
  37. 7.7 Zydus
  38. 7.7.1 Zydus Company Information
  39. 7.7.2 Zydus Business Overview
  40. 7.7.3 Zydus Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Zydus Oral Medications for Multiple Sclerosis Product Portfolio
  42. 7.7.5 Zydus Recent Developments
  43. 7.8 Viatris
  44. 7.8.1 Viatris Company Information
  45. 7.8.2 Viatris Business Overview
  46. 7.8.3 Viatris Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Viatris Oral Medications for Multiple Sclerosis Product Portfolio
  48. 7.8.5 Viatris Recent Developments
  49. 7.9 Teva
  50. 7.9.1 Teva Company Information
  51. 7.9.2 Teva Business Overview
  52. 7.9.3 Teva Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Teva Oral Medications for Multiple Sclerosis Product Portfolio
  54. 7.9.5 Teva Recent Developments
  55. 7.10 Sun Pharmaceuticals
  56. 7.10.1 Sun Pharmaceuticals Company Information
  57. 7.10.2 Sun Pharmaceuticals Business Overview
  58. 7.10.3 Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Sun Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio
  60. 7.10.5 Sun Pharmaceuticals Recent Developments
  61. 7.11 Sanofi
  62. 7.11.1 Sanofi Company Information
  63. 7.11.2 Sanofi Business Overview
  64. 7.11.3 Sanofi Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Sanofi Oral Medications for Multiple Sclerosis Product Portfolio
  66. 7.11.5 Sanofi Recent Developments
  67. 7.12 Sandoz
  68. 7.12.1 Sandoz Company Information
  69. 7.12.2 Sandoz Business Overview
  70. 7.12.3 Sandoz Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Sandoz Oral Medications for Multiple Sclerosis Product Portfolio
  72. 7.12.5 Sandoz Recent Developments
  73. 7.13 Novartis
  74. 7.13.1 Novartis Company Information
  75. 7.13.2 Novartis Business Overview
  76. 7.13.3 Novartis Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Novartis Oral Medications for Multiple Sclerosis Product Portfolio
  78. 7.13.5 Novartis Recent Developments
  79. 7.14 Mylan
  80. 7.14.1 Mylan Company Information
  81. 7.14.2 Mylan Business Overview
  82. 7.14.3 Mylan Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Mylan Oral Medications for Multiple Sclerosis Product Portfolio
  84. 7.14.5 Mylan Recent Developments
  85. 7.15 Merck
  86. 7.15.1 Merck Company Information
  87. 7.15.2 Merck Business Overview
  88. 7.15.3 Merck Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Merck Oral Medications for Multiple Sclerosis Product Portfolio
  90. 7.15.5 Merck Recent Developments
  91. 7.16 Janssen
  92. 7.16.1 Janssen Company Information
  93. 7.16.2 Janssen Business Overview
  94. 7.16.3 Janssen Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Janssen Oral Medications for Multiple Sclerosis Product Portfolio
  96. 7.16.5 Janssen Recent Developments
  97. 7.17 Glenmark Pharmaceuticals
  98. 7.17.1 Glenmark Pharmaceuticals Company Information
  99. 7.17.2 Glenmark Pharmaceuticals Business Overview
  100. 7.17.3 Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Glenmark Pharmaceuticals Oral Medications for Multiple Sclerosis Product Portfolio
  102. 7.17.5 Glenmark Pharmaceuticals Recent Developments
  103. 7.18 Dr. Reddy's Laboratories
  104. 7.18.1 Dr. Reddy's Laboratories Company Information
  105. 7.18.2 Dr. Reddy's Laboratories Business Overview
  106. 7.18.3 Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Dr. Reddy's Laboratories Oral Medications for Multiple Sclerosis Product Portfolio
  108. 7.18.5 Dr. Reddy's Laboratories Recent Developments
  109. 7.19 Bristol Myers Squibb
  110. 7.19.1 Bristol Myers Squibb Company Information
  111. 7.19.2 Bristol Myers Squibb Business Overview
  112. 7.19.3 Bristol Myers Squibb Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Bristol Myers Squibb Oral Medications for Multiple Sclerosis Product Portfolio
  114. 7.19.5 Bristol Myers Squibb Recent Developments
  115. 7.20 Biogen
  116. 7.20.1 Biogen Company Information
  117. 7.20.2 Biogen Business Overview
  118. 7.20.3 Biogen Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Biogen Oral Medications for Multiple Sclerosis Product Portfolio
  120. 7.20.5 Biogen Recent Developments
  121. 7.21 Banner Life Sciences
  122. 7.21.1 Banner Life Sciences Company Information
  123. 7.21.2 Banner Life Sciences Business Overview
  124. 7.21.3 Banner Life Sciences Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 Banner Life Sciences Oral Medications for Multiple Sclerosis Product Portfolio
  126. 7.21.5 Banner Life Sciences Recent Developments
  127. 7.22 Apotex
  128. 7.22.1 Apotex Company Information
  129. 7.22.2 Apotex Business Overview
  130. 7.22.3 Apotex Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  131. 7.22.4 Apotex Oral Medications for Multiple Sclerosis Product Portfolio
  132. 7.22.5 Apotex Recent Developments
  133. 7.23 Alembic
  134. 7.23.1 Alembic Company Information
  135. 7.23.2 Alembic Business Overview
  136. 7.23.3 Alembic Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  137. 7.23.4 Alembic Oral Medications for Multiple Sclerosis Product Portfolio
  138. 7.23.5 Alembic Recent Developments
  139. 7.24 Accord Healthcare
  140. 7.24.1 Accord Healthcare Company Information
  141. 7.24.2 Accord Healthcare Business Overview
  142. 7.24.3 Accord Healthcare Oral Medications for Multiple Sclerosis Sales, Revenue, Price and Gross Margin (2021-2026)
  143. 7.24.4 Accord Healthcare Oral Medications for Multiple Sclerosis Product Portfolio
  144. 7.24.5 Accord Healthcare Recent Developments
8 North America
  1. 8.1 North America Oral Medications for Multiple Sclerosis Market Size by Type
  2. 8.1.1 North America Oral Medications for Multiple Sclerosis Revenue by Type (2021-2032)
  3. 8.1.2 North America Oral Medications for Multiple Sclerosis Sales by Type (2021-2032)
  4. 8.1.3 North America Oral Medications for Multiple Sclerosis Price by Type (2021-2032)
  5. 8.2 North America Oral Medications for Multiple Sclerosis Market Size by Application
  6. 8.2.1 North America Oral Medications for Multiple Sclerosis Revenue by Application (2021-2032)
  7. 8.2.2 North America Oral Medications for Multiple Sclerosis Sales by Application (2021-2032)
  8. 8.2.3 North America Oral Medications for Multiple Sclerosis Price by Application (2021-2032)
  9. 8.3 North America Oral Medications for Multiple Sclerosis Market Size by Country
  10. 8.3.1 North America Oral Medications for Multiple Sclerosis Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Oral Medications for Multiple Sclerosis Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Oral Medications for Multiple Sclerosis Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Oral Medications for Multiple Sclerosis Market Size by Type
  2. 9.1.1 Europe Oral Medications for Multiple Sclerosis Revenue by Type (2021-2032)
  3. 9.1.2 Europe Oral Medications for Multiple Sclerosis Sales by Type (2021-2032)
  4. 9.1.3 Europe Oral Medications for Multiple Sclerosis Price by Type (2021-2032)
  5. 9.2 Europe Oral Medications for Multiple Sclerosis Market Size by Application
  6. 9.2.1 Europe Oral Medications for Multiple Sclerosis Revenue by Application (2021-2032)
  7. 9.2.2 Europe Oral Medications for Multiple Sclerosis Sales by Application (2021-2032)
  8. 9.2.3 Europe Oral Medications for Multiple Sclerosis Price by Application (2021-2032)
  9. 9.3 Europe Oral Medications for Multiple Sclerosis Market Size by Country
  10. 9.3.1 Europe Oral Medications for Multiple Sclerosis Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Oral Medications for Multiple Sclerosis Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Oral Medications for Multiple Sclerosis Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Oral Medications for Multiple Sclerosis Market Size by Type
  2. 10.1.1 China Oral Medications for Multiple Sclerosis Revenue by Type (2021-2032)
  3. 10.1.2 China Oral Medications for Multiple Sclerosis Sales by Type (2021-2032)
  4. 10.1.3 China Oral Medications for Multiple Sclerosis Price by Type (2021-2032)
  5. 10.2 China Oral Medications for Multiple Sclerosis Market Size by Application
  6. 10.2.1 China Oral Medications for Multiple Sclerosis Revenue by Application (2021-2032)
  7. 10.2.2 China Oral Medications for Multiple Sclerosis Sales by Application (2021-2032)
  8. 10.2.3 China Oral Medications for Multiple Sclerosis Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Oral Medications for Multiple Sclerosis Market Size by Type
  2. 11.1.1 Asia Oral Medications for Multiple Sclerosis Revenue by Type (2021-2032)
  3. 11.1.2 Asia Oral Medications for Multiple Sclerosis Sales by Type (2021-2032)
  4. 11.1.3 Asia Oral Medications for Multiple Sclerosis Price by Type (2021-2032)
  5. 11.2 Asia Oral Medications for Multiple Sclerosis Market Size by Application
  6. 11.2.1 Asia Oral Medications for Multiple Sclerosis Revenue by Application (2021-2032)
  7. 11.2.2 Asia Oral Medications for Multiple Sclerosis Sales by Application (2021-2032)
  8. 11.2.3 Asia Oral Medications for Multiple Sclerosis Price by Application (2021-2032)
  9. 11.3 Asia Oral Medications for Multiple Sclerosis Market Size by Country
  10. 11.3.1 Asia Oral Medications for Multiple Sclerosis Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Oral Medications for Multiple Sclerosis Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Oral Medications for Multiple Sclerosis Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Oral Medications for Multiple Sclerosis Market Size by Type
  2. 12.1.1 SAMEA Oral Medications for Multiple Sclerosis Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Oral Medications for Multiple Sclerosis Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Oral Medications for Multiple Sclerosis Price by Type (2021-2032)
  5. 12.2 SAMEA Oral Medications for Multiple Sclerosis Market Size by Application
  6. 12.2.1 SAMEA Oral Medications for Multiple Sclerosis Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Oral Medications for Multiple Sclerosis Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Oral Medications for Multiple Sclerosis Price by Application (2021-2032)
  9. 12.3 SAMEA Oral Medications for Multiple Sclerosis Market Size by Country
  10. 12.3.1 SAMEA Oral Medications for Multiple Sclerosis Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Oral Medications for Multiple Sclerosis Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Oral Medications for Multiple Sclerosis Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Oral Medications for Multiple Sclerosis Value Chain Analysis
  2. 13.1.1 Oral Medications for Multiple Sclerosis Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Oral Medications for Multiple Sclerosis Production Mode & Process
  6. 13.2 Oral Medications for Multiple Sclerosis Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Oral Medications for Multiple Sclerosis Distributors
  9. 13.2.3 Oral Medications for Multiple Sclerosis Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst